A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT ID: NCT06782490
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
200 participants
INTERVENTIONAL
2025-06-05
2027-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BX-1 in Spasticity Due to Multiple Sclerosis
NCT03756974
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
NCT04984278
Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
NCT01868048
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
NCT00468611
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
NCT00702468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Administration of BMS-986368 Dose A
BMS-986368
Specified dose on specified days
Administration of BMS-986368 Dose B
BMS-986368
Specified dose on specified days
Administration of BMS-986368 Dose C
BMS-986368
Specified dose on specified days
Placebo
Placebo
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986368
Specified dose on specified days
Placebo
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have a history of spasticity due to MS for at least 6 months prior to Visit 1.
* Participants must have a Modified Ashworth Scale (mAS) score ≥2 in each of 2 muscle groups (at least one muscle group in the leg, excluding ankle plantar flexors) at Visit 1.
* Participants must have an Expanded Disability Status Scale (EDSS) score 3.0-6.5 at Visit 1.
Exclusion Criteria
* Participants must not have an acute MS exacerbation/relapse requiring treatment or alteration in disease modifying drug dose within 3 months of Visit 1 or Visit 2.
* Participants must not have a history of any substance abuse disorder as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Diagnostic Criteria for Drug and Alcohol Abuse.
* Participants must not be currently taking a medication for spasticity that cannot be discontinued and washed out by Visit 2.
* Participants must not have used FAAH/MAGL inhibitor medication or any cannabinoid-related products (including cannabis, cannabidiol (CBD), or tetrahydrocannabinol (THC)) within 30 days prior to Visit 1.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0033
Birmingham, Alabama, United States
Perseverance Research Center,LLC
Scottsdale, Arizona, United States
Local Institution - 0017
Aurora, Colorado, United States
Local Institution - 0068
Naples, Florida, United States
USF Health
Tampa, Florida, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Neurology Center of New England
Foxborough, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Local Institution - 0039
Columbus, Ohio, United States
Local Institution - 0069
Columbus, Ohio, United States
Local Institution - 0067
Philadelphia, Pennsylvania, United States
Hope Neurology
Knoxville, Tennessee, United States
EvergreenHealth Medical Center
Kirkland, Washington, United States
John Hunter Hospital
Newcastle, New South Wales, Australia
University of Sydney - Brain and Mind Research Institute (BMRI)
Sydney, New South Wales, Australia
Centre for Neuroscience Innovation
Kent Town, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
Perron Institute
Nedlands, Western Australia, Australia
Local Institution - 0013
Edmonton, Alberta, Canada
Local Institution - 0024
London, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Local Institution - 0028
Toronto, Ontario, Canada
Centre de Recherche Saint-Louis
Lévis, Quebec, Canada
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada
Fakultni Nemocnice u sv. Anny v Brne
Brno, Brno-město, Czechia
Local Institution - 0010
Hradec Králové, Hradec Králové, Czechia
Vseobecna fakultni nemocnice v Praze
Prague, Praha 2, Czechia
Fakultni Thomayerova nemocnice
Prague, Praha 4, Czechia
Local Institution - 0011
Prague, Praha 5, Czechia
Local Institution - 0053
Pardubice, , Czechia
Local Institution - 0009
Teplice, Ústecký kraj, Czechia
Klinikum Würzburg Mitte
Würzburg, Bavaria, Germany
Neurologischen Gemeinschaftspraxis Kassel und Vellmar
Kassel, Hesse, Germany
St. Josef und St. Elisabeth Hospital gGmbH
Bochum, North Rhine-Westphalia, Germany
Local Institution - 0060
Münster, North Rhine-Westphalia, Germany
Local Institution - 0031
Meisenheim, Rhineland-Palatinate, Germany
Universitätsklinikum Jena
Jena, Thuringia, Germany
Neurozentrum Bielefeld
Bielefeld, , Germany
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Local Institution - 0020
Essen, , Germany
Centrum Medyczne NEUROMED
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Local Institution - 0044
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Pratia MCM Krakow
Krakow, Lesser Poland Voivodeship, Poland
SP ZOZ Szpital Uniwersytecki w Krakowie
Krakow, Lesser Poland Voivodeship, Poland
Instytut Zdrowia Dr Boczarska Jedynak
Oświęcim, Lesser Poland Voivodeship, Poland
Local Institution - 0070
Lódz, Lódzkie, Poland
Centrum Medyczne NeuroProtect
Warsaw, Masovian Voivodeship, Poland
Local Institution - 0061
Gdansk, , Poland
Local Institution - 0045
Katowice, , Poland
Local Institution - 0051
Słomniki, , Poland
Puerto Rico Multiple Sclerosis Center
Caguas, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role: CONTACT
First line of the email MUST contain the NCT# and Site#
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site 0033
Role: primary
Barry Hendin, Site 0050
Role: primary
Site 0068
Role: primary
Derrick Robertson, Site 0015
Role: primary
Sharon Lynch, Site 0016
Role: primary
Andrew Taylor, Site 0049
Role: primary
Robert Naismith, Site 0018
Role: primary
Shahla Hosseini, Site 0002
Role: primary
Site 0039
Role: primary
Site 0069
Role: primary
Site 0067
Role: primary
Sibyl Wray, Site 0003
Role: primary
Theodore Brown, Site 0001
Role: primary
Jeannette Lechner-Scott, Site 0005
Role: primary
Michael Barnett, Site 0004
Role: primary
Andrew Lee, Site 0030
Role: primary
Katherine Buzzard, Site 0007
Role: primary
Marion Simpson, Site 0008
Role: primary
Mark Marriott, Site 0006
Role: primary
william Carroll, Site 0019
Role: primary
Site 0013
Role: primary
Site 0024
Role: primary
Mark Freedman, Site 0012
Role: primary
Site 0028
Role: primary
Donald Rivest, Site 0014
Role: primary
Adil Harroud, Site 0029
Role: primary
Martin Pail, Site 0055
Role: primary
Site 0010
Role: primary
Ivana Kovářová, Site 0054
Role: primary
Marketa Grunermelova, Site 0059
Role: primary
Site 0053
Role: primary
Site 0009
Role: primary
Mathias Mäurer, Site 0052
Role: primary
Christoph Lassek, Site 0022
Role: primary
Simon Faissner, Site 0027
Role: primary
Site 0060
Role: primary
Matthias Schwab, Site 0023
Role: primary
Matthias Böhringer, Site 0051
Role: primary
Tjalf Ziemssen, Site 0021
Role: primary
Site 0020
Role: primary
Pawel Lisewski, Site 0057
Role: primary
Site 0044
Role: primary
Paulina Kaczmarska, Site 0046
Role: primary
Agnieszka Slowik, Site 0056
Role: primary
Magdalena Boczarska-Jedynak, Site 0048
Role: primary
Site 0070
Role: primary
Anna Karlinska, Site 0047
Role: primary
Site 0045
Role: primary
Jose Avila Ornelas, Site 0058
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM045-1018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.